Abstract | INTRODUCTION: AREAS COVERED: This article examines the safety and efficacy of valganciclovir in pediatric SOT patients, with a particular focus on prophylaxis of CMV infections. An in-depth review of the literature, including pertinent data from the adult SOT population, and a discussion of unmet needs are provided. The pharmacokinetics and pharmacodynamics of valganciclovir in the pediatric population are also discussed. EXPERT OPINION: Existing evidence supports the use of valganciclovir in pediatric SOT patients for CMV prophylaxis. Although comprehensive data are lacking, valganciclovir is a treatment option for CMV infection in pediatric SOT patients. The role of valganciclovir in pediatrics is expected to grow given its demonstrated efficacy in a variety of clinical settings and its advantages over ganciclovir.
|
Authors | Marie A Yu, Jeong M Park |
Journal | Expert opinion on pharmacotherapy
(Expert Opin Pharmacother)
Vol. 14
Issue 6
Pg. 807-15
(Apr 2013)
ISSN: 1744-7666 [Electronic] England |
PMID | 23469871
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)
|
Chemical References |
- Antiviral Agents
- Prodrugs
- Valganciclovir
- Ganciclovir
|
Topics |
- Administration, Oral
- Adult
- Antiviral Agents
(adverse effects, pharmacokinetics, therapeutic use)
- Biological Availability
- Child
- Cytomegalovirus Infections
(prevention & control)
- Ganciclovir
(adverse effects, analogs & derivatives, pharmacokinetics, therapeutic use)
- Humans
- Opportunistic Infections
(prevention & control, virology)
- Organ Transplantation
(methods)
- Prodrugs
- Valganciclovir
|